Pfizer has patented CARs that target BCMA for treating conditions related to malignant cells expressing BCMA, like cancer. The method involves administering engineered immune cells with specific CARs to patients. The CARs contain unique ligand-binding domains and signaling domains for effective treatment. GlobalData’s report on Pfizer gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Pfizer, Cancer treatment biomarkers was a key innovation area identified from patents. Pfizer's grant share as of February 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of cancer using engineered immune cells targeting bcma
A recently granted patent (Publication Number: US11912776B2) discloses a method for treating conditions associated with malignant cells expressing B-cell maturation antigen (BCMA) in a subject. The method involves administering a pharmaceutical composition comprising an engineered immune cell expressing a BCMA-specific chimeric antigen receptor (CAR) to the subject. The CAR includes specific amino acid sequences for the extracellular ligand-binding domain, transmembrane domain, and intracellular signaling domain. The engineered immune cell is designed to target BCMA-expressing malignant cells effectively. Additionally, the patent outlines various specific sequences and configurations for the CAR components, including VH and VL regions, transmembrane domains, and signaling domains, to enhance the therapeutic efficacy of the treatment.
Furthermore, the patent details the inclusion of a CD20 epitope in the BCMA-specific CAR, along with other components like a stalk domain, additional extracellular ligand-binding domains, and the potential disruption of endogenous genes encoding immune checkpoint proteins. The method also covers the selection of different types of engineered immune cells, such as T cells, dendritic cells, NK cells, and B cells, for the treatment. By providing a comprehensive framework for utilizing engineered immune cells with specific CAR configurations to target BCMA-expressing malignant cells, this patent offers a promising approach for treating conditions associated with such malignancies. The detailed sequences and compositions outlined in the patent aim to optimize the therapeutic potential of the engineered immune cells in combating BCMA-positive malignancies, potentially leading to more effective and targeted treatment options for patients in need.
To know more about GlobalData’s detailed insights on Pfizer, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
